Revolution Medicines has seen promising results from an early-stage study of its experimental treatment for pancreatic cancer. The treatment targets the RAS family of proteins, which are often mutated in cancer cells. The company’s drug, RMC-6236, led to a median progression-free survival of 8.1 months in patients with specific mutations. A Phase 3 study is planned to compare this treatment to standard chemotherapy. Revolution is also developing treatments for non-small cell lung cancer and solid tumors. The company’s technology platform is seen as competitive in the field of RAS drug development, with plans to release updates later this year.
Source link
Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug
